Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1/2 11Phase 1 10Phase 3 7Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 2Not yet recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 4Prostatic Diseases 1Prostate Cancer Metastatic 1Kidney Neoplasms 1Genital Diseases, Male 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 77Radiotherapy 73Prednisone 66Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 43Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 31Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Nivolumab 24Triptorelin Pamoate 23Sunitinib 23apalutamide 22Radiation 22Doxorubicin 20darolutamide 19abiraterone 18Gonadotropin-Releasing Hormone 18cabozantinib 17atezolizumab 16Specimen Handling 16Radiosurgery 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Pluvicto × Genitourinary × Clear all
NCT04720157 2026-05-27

PSMAddition

Novartis

Phase 3 Active not recruiting
1,140 enrolled
Genitourinary

Prostatic Neoplasms

NCT04689828 2026-03-23

PSMAfore

Novartis

Phase 3 Active not recruiting
469 enrolled 11 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT06959433 2026-02-27

Lu-177 PSMA Treatment in Cell Renal Carcinoma

Ankara University

Phase 3 Not yet recruiting
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07200830 2025-10-01

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
1,524 enrolled
Genitourinary

Prostatic Neoplasms

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting
3,360 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT03511664 2025-01-13

VISION

Endocyte

Phase 3 Completed
861 enrolled 39 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡